WCLC 2022 | Combining radiotherapy with novel agents in NSCLC

Gerard M. Walls, MB, MRCP, MSc, FRCR, Queen’s University Belfast, Belfast, UK, provides the rationale behind combining novel agents with conventional radiotherapy in non-small cell lung cancer (NSCLC), as investigated in the Phase I CONCORDE (NCT04550104) trial. Many patients are unable to tolerate chemotherapy concurrently with radiotherapy, however, novel radiosensitizing agents could improve the effectiveness of radiotherapy so chemotherapy can be avoided. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.